Tao Synergies Inc. · NASDAQ:TAOX
Tao Synergies — NanoVibronix — Shareholder Meeting (December 2024)
12 slides from Tao Synergies's shareholder meeting presentation, Dec 19, 2024
Slide 1: NanoVibronix Annual Stockholder Meeting
NanoVibronix Annual Stockholderholder Meeting December 19, 2024 © 2024 NanoVibronix, Inc.
Slide 2: Safe Harbor Disclaimer
Safe Harbor Disclaimer This presentation may contain “forward-looking statements” that are made pursuant to the “safe harbor” provisions as defined within the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including “intends,” “may,” “will,” “
Slide 3: At A Glance
At A Glance Who We Are • NanoVibronix is a Nasdaq listed, international medical device company utilizing its patented, proprietary platform technology to achieve positive clinical outcomes. Through a variety of indications, we offer a unique and effective alternative for both treatment and preventio
Slide 4: At A Glance- cont'd
At A Glance- cont’d Our Technology UroShield TM • Our products employ small, disposable transducers that transmit low frequency, low intensity ultrasound acoustic waves. • These devices address a range of clinical applications helping eliminate pain, repair and regenerate tissue in musculoskeletal /
Slide 5: UroShield
UroShield UroShield (Our Flagship Product) • A therapeutic surface acoustic wave device, consisting of a reusable driver unit and a clamp- on disposable, which contains a proprietary therapeutic transducer. • Designed to prevent bacterial docking, colonization and biofilm on indwelling urinary cathe
Slide 6: The Problem: Catheter Associated Urinary Tract Infection (CAUTI)
The Problem: Catheter Associated Urinary Tract Infection (CAUTI) ❑ UTIs account for 40% of nosocomial infections ❑ Main risk: catheter induced infections (3-10% daily incremental increase in risk) ❑ Biofilms cause over 80% of infections ❑ Frequent use of antibiotics increase multi-drug resistance ❑
Slide 7: Gold Standard Study to Facilitate Permanent FDA 510K
Gold Standard Study to Facilitate Permanent FDA 510K Dr. Luna Mody M.D, M.P.H. Clinical End-Point Options (Principal Investigator) Patient Reported Outcomes 1. Reduction of Pain University of Michigan 2.Catheter Blockage 3.Quality of Life Professor of Internal Medicine 4.Antibiotic Usage MD at VA An
Slide 8: The Problem: Pain is prevalent with limited long-term solutions
The Problem: Pain is prevalent with limited long-term solutions ❑ Chronic pain affects 21% of US adults ❑ 6.9% of US adults experience high impact chronic pain ❑ Opioid use continues to escalate ❑ High incidence of pain related injuries in workers‘ compensation claims ❑ High incidence of pain among
Slide 9: PainShield: Summary
PainShield: Summary ❑ Opioid alternative- “Slow Release” - low intensity, low frequency ultrasound ❑ Treating wide surface ❑ Anywhere & anytime - portable, does not require clinical setting ❑ Convenient, wearable hands-free application ❑ Allows treatment for difficult to access sites ❑ No known side
Slide 10: Recent Developments
Recent Developments The University of Michigan (“UM”)- trial study ➢ In 2024, UM began facilitating a gold standard Randomized Control Trial study on the Logistics, efficacy, and patient satisfaction of patients utilizing UroShield. Expecting pilot study results soon. Apogepha Pharmaceutical (“Apoge
Slide 11: Recent Developments-cont'd
Recent Developments-cont’d Working Toward Full NHS Reimbursement for UroShield ➢ Progressing on full UroShield NHS reimbursement through the UK “Drug Tariff” program ➢ Currently, UroShield disposable products are fully reimbursed Workers Compensation and Veterans Administration Network is Growing ➢
Slide 12: Business Summary
Business Summary ✓ Breakthrough medical platform and devices ✓ Extensive existing and growing clinical evidence and regulatory approvals ✓ Several catalysts for growth ✓ Redesigned, Enhancement, and “Future-Proofing” all products ✓ Addresses multi-billion $ markets - catheter infections, pain relief